A New Era in Bladder Cancer Treatment: Pfizer’s Sasanlimab Hits the Mark Pfizer has unveiled groundbreaking Phase 3 results for its investigational PD-1 inhibitor, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG), a long-standing standard of care for high-ris...

www.linkedin.com/pulse/new-er...

A New Era in Bladder Cancer Treatment: Pfizer’s Sasanlimab Hits the Mark

kstrategyand.com/pharma-news

#Pfizer #Sasanlimab #BCG #CancerResearch #BladderCancerAwareness #NewTreatment #PharmaceuticalInnovation #HealthCare #Humanteconomy #Humantec #KStrategyand

Weekly Roundup - PHARMA - 20 January 2025 🔊Autolus Therapeutics Secures FDA Approval for Aucatzyl Cell Therapy in Relapsed B-Cell Leukemia Autolus Therapeutics is launching Aucatzyl commercially in the U.S.

🚀 Weekly Roundup - PHARMA - 20 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#AutolusTherapeutics #BannerLifeSciences #Bafiertam #Pfizer #Sasanlimab #TyraBiosciences #ImmunoForge #Pemziviptadil #PharmaNews #ClinicalTrials #Humanteconomy #Humantec #KStrategyand

Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer - OncoDaily Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer / bladder cancer, cancer, event-free survival (EFS), Neal Shore,

Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer

oncodaily.com/insight/sasa...

#BladderCancer #Cancer #EventFreeSurvival #EFS #OncoDaily #Oncology #Pfizer #Sasanlimab

#CREST trial with positive results for #PD-1 in HR #NMIBC!
✅The study evaluated #sasanlimab (PD-1i)+BCG vs standard #BCG (induction + maintenance) in BCG-naïve, HR NMIBC.
✅The study met its primary endpoint with significant improvement of EFS
pfizer.com/news/press-rel…
@oncodaily.bsky.social